Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05734625 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Nerve Blocks for Episodic Migraine
A Phase 2 study of Episodic Migraine, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05734625: Recruiting Phase 2 study of Episodic Migraine, sponsored by Mayo Clinic.
NCT05734625 is a Phase 2 study of Episodic Migraine that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 492-participant average among 13 other Episodic Migraine trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05734625, a Phase 2 study of Episodic Migraine, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine anesthetic (numbing medication) and low dose methylprednisolone (cortisone-like medicine or steroid) work for treating and preventing migraines. Our hypothesis is that the pain of most episodic migraine headaches can be eliminated and prevented for months by blocking the nerves that give pain sensation during a migraine.
Primary Outcome
Number of subjects to experience an elimination of acute headache (pain freedom) defined as pain 0/10
Conditions Studied
Interventions
- DRUG Bupivacaine HCl 0.5% Injectable Solution
- DRUG Methylprednisolone 40 MG Injection
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What NCT05734625 shows while recruiting
NCT05734625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 492-participant average among 13 other Episodic Migraine trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine HCl 0.5% Injectable Solution is the first listed.
NCT05734625 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05734625 about?
NCT05734625 is a clinical study titled "Efficacy of Nerve Blocks for Episodic Migraine". The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine anesthetic (numbing medication) and low dose methylprednisolone (cortisone-like medicine or steroid) work for treating and ...
What is the current status of trial NCT05734625?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-07-10. Estimated completion is 2027-07.
What conditions does trial NCT05734625 study?
This clinical trial studies the following conditions: Episodic Migraine.
What interventions are being tested in trial NCT05734625?
The interventions under investigation include: Bupivacaine HCl 0.5% Injectable Solution (DRUG), Methylprednisolone 40 MG Injection (DRUG).
Who is sponsoring clinical trial NCT05734625?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05734625 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Episodic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05734625's enrollment target sits among peer trials
60 13th of 13 the lowest of 13 other Episodic Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Episodic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
RECRUITING · Phase 3
-
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
RECRUITING · Phase 3
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RECRUITING
-
Chiropractic Care for Episodic Migraine
RECRUITING · NA
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI